Cite
MLA Citation
Shaker Dakhil et al.. “Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.” Leukemia & lymphoma, vol. 55, no. 10, n.d., pp. 2335–2340. http://access.bl.uk/ark:/81055/vdc_100024950471.0x000031